They showed more significant tumor regressions with dual pathway inhibition via Enzalutamide and rapamycin rather than single pathway inhibition in both PTEN null/AR+ prostate cancer cell lines and PTEN null mice. This evidence concerns the gene AR and Familial prostate cancer.